← TrialMatch
HomeTrials

Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Hum

Evaluate the safety and preliminary efficacy of human induced pluripotent stem cell-derived extracellular vesicle (iEV) injection in the treatment of lateral epicondylitis of the humerus.

Condition(s)Lateral Epicondylitis
StatusRecruiting
PhasePhase 1, Phase 2
Study typeInterventional
SummaryEvaluate the safety and preliminary efficacy of human induced pluripotent stem cell-derived extracellular vesicle (iEV) injection in the treatment of lateral epicondylitis of the humerus.
Who can participateInclusion Criteria: * Diagnosed with lateral epicondylitis by clinical symptom examination and MRI or ultrasound, without obvious tendon tear; * Unilateral lateral elbow pain lasting for more than 12 weeks; * Pain is provoked by at least 2 of the following methods, with a pain VAS score exceeding 3: maximum grip strength, palpation of the lateral epicondyle of the elbow and surrounding area, resisted dorsiflexion of the wrist or middle finger, or stretching of the forearm extensor muscles under a pain-free grip state; * Having received physical therapy or non-steroidal anti-inflammatory drug treatment with poor efficacy; * Individuals with independent behavioral capacity, who have signed the informed consent form themselves. Exclusion Criteria: * Complaints of ipsilateral muscle pain cause
Ages18 Years
SexAll
Lead sponsorShanghai 6th People's Hospital
LocationsShanghai, Shanghai Municipality, China
Start date2023-07-01
NCT IDNCT07111325
Official listinghttps://clinicaltrials.gov/study/NCT07111325

🔍 Search all trials →